Memphis, TN May 10th, 2023 - Hera Health Solutions, a pharmaceutical device company specializing in the research, development, and commercialization of long-acting treatments through proprietary bioerodible drug delivery implants, has been awarded a SBIR grant from the National Science Foundation (NSF) to support the expansion of its research and development operations. The grant will enable Hera to accelerate the development of its innovative products and technologies, ultimately propelling the company’s technologies to market to help patients receive long-acting treatments through biodegradable drug delivery implants.
The NSF grant is a significant milestone for Hera Health Solutions, highlighting the company's commitment to advancing drug delivery innovation. The funding will allow Hera to expand its R&D team, expand its cutting-edge nanotechnology-based manufacturing, and accelerate the development of its flagship product, ‘Eucontra’.
"We are honored to receive this award from the NSF, and it further highlights the need for innovative technologies in the drug delivery space," said Idicula Mathew, CEO of Hera Health Solutions. "Our team is committed to developing out this innovative technology in pharmaceuticals, and we look forward to this partnership with the NSF”.
Hera Health Solutions uses nanotechnology to develop biodegradable drug delivery scaffolds, allowing patients to receive long-acting treatments through biodegradable drug delivery implants that can last many weeks to months. Their first product under development, Eucontra, is a first-of-its-kind biodegradable contraceptive-releasing implant, offering patients a discreet and convenient alternative to traditional contraceptive methods. The company is also pursuing testing and development of products in a multitude of other long-acting therapeutic areas, including opioid addiction treatment and animal health products.
The NSF grant will support Hera's ongoing efforts to expand its product line and bring new, innovative products to market. With the support of the NSF, Hera is poised to make significant strides in the field of drug delivery and help patients receive long-acting treatments through biodegradable drug delivery scaffolded implants.
About Hera Health Solutions:
Hera Health Solutions is a pharmaceutical device company specializing in the research, development, and commercialization of long-acting treatments through proprietary bioerodible drug delivery implants. The company uses nanotechnology to develop biodegradable drug delivery scaffolds, allowing patients to receive long-acting treatments through biodegradable drug-delivery implants that can last weeks or months. Their first product under development, Eucontra, is a first-of-its-kind biodegradable contraceptive-releasing implant. The company is also pursuing testing and development of products in a multitude of other long-acting therapeutic areas, including opioid addiction treatment and animal health products.
For more information about Hera Health Solutions, please visit www.herahealthsolutions.com.
About the The U.S. National Science Foundation:
The U.S. National Science Foundation is an independent federal agency that supports science and engineering in all 50 states and U.S. territories.
NSF was established in 1950 by Congress to: 1) Promote the progress of science. 2) Advance the national health, prosperity and welfare. 3) Secure the national defense.
###